EMANATE is a phase III trial comprising five independent sub-studies based on genetic variants that is currently underway (ClinicalTrials.gov identifier: NCT05093634).85 Participants must have a heterozygous genetic variant in POMC or PCSK1, LEPR, and SRC1 or SH2B1 obesity. This evidence concerns the gene POMC and obesity due to melanocortin 4 receptor deficiency.